RISK OF RECURRENCE AMONG PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, EARLY BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Ramirez, Oliva A. [1 ]
Law, E. H. [2 ]
Cueto, J. [2 ]
Salvo, E. M. [1 ]
Situ, A. [1 ]
Samjoo, I. A. [1 ]
机构：
[1] EVERSANA, Burlington, ON, Canada
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN43
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [21] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [22] Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
    Stefania Morganti
    Antonio Marra
    Edoardo Crimini
    Paolo D’Amico
    Paola Zagami
    Giuseppe Curigliano
    Breast Cancer Research and Treatment, 2022, 192 : 465 - 484
  • [23] ASCO 2019—Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC
    Semir Beslija
    memo - Magazine of European Medical Oncology, 2019, 12 : 305 - 307
  • [24] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [25] Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
    Morganti, Stefania
    Marra, Antonio
    Crimini, Edoardo
    D'Amico, Paolo
    Zagami, Paola
    Curigliano, Giuseppe
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (03) : 465 - 484
  • [26] Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
    Wilson, Florence R.
    Varu, Abhishek
    Mitra, Debanjali
    Cameron, Chris
    Iyer, Shrividya
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 167 - 177
  • [27] Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
    Jeong, Eunae
    Wang, Changjun
    Wilson, Leslie
    Zhong, Lixian
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [28] Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
    Le, Vivian
    Zhong, Lixian
    Narsipur, NihaL
    Hays, Elizabeth
    Tran, Daniel Khuong
    Rosario, Kimberly
    Wilson, Leslie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (03): : 327 - 338
  • [29] Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
    Florence R. Wilson
    Abhishek Varu
    Debanjali Mitra
    Chris Cameron
    Shrividya Iyer
    Breast Cancer Research and Treatment, 2017, 166 : 167 - 177
  • [30] Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis
    Kubeczko, Marcin
    Jarzab, Michal
    Gabrys, Dorota
    Krzywon, Aleksandra
    Cortez, Alexander J.
    Xu, Amy J.
    RADIOTHERAPY AND ONCOLOGY, 2023, 187
12345